Study #2019-1098
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies (AB680CSP0002)
MD Anderson Study Status
Not Accepting
Treatment Agent
AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine
Description
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Pancreatic Cancer
Study phase:
Phase I
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-403-3911
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.